Supplementary Figure S3 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Year: 2024
Type: supplementary-materials
Abstract: Genes differentially expressed as a function of BOR on cycle 3 day 1. Genes differentially expressed on C3D1 versus treatment baseline, as a function of TPST-1120 exposure. Linear associations of C3D1 Log2 fold change in expression levels of indicated genes and TPST-1120 AUC0-24. Data are shown for both TPST-1120 monotherapy (part 1) and TPST-1120 + nivolumab combination therapy (part 2).
Authors: Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4394915067